Distinct distribution and prognostic significance of molecular subtypes of breast cancer in Chinese women: a population-based cohort study
Open Access
- 12 July 2011
- journal article
- research article
- Published by Springer Science and Business Media LLC in BMC Cancer
- Vol. 11 (1), 292
- https://doi.org/10.1186/1471-2407-11-292
Abstract
Background Molecular classification of breast cancer is an important prognostic factor. The distribution of molecular subtypes of breast cancer and their prognostic value has not been well documented in Asians. Methods A total of 2,791 breast cancer patients recruited for a population-based cohort study were evaluated for molecular subtypes of breast cancer by immunohistochemical assays. Data on clinicopathological characteristics were confirmed by centralized pathology review. The average follow-up of the patients was 53.4 months. Overall and disease-free survival by molecular subtypes of breast cancer were evaluated. Results The prevalence of the luminal A, luminal B, human epidermal growth factor receptor 2 (HER2), and triple-negative subtypes were 48.6%, 16.7%, 13.7%, and 12.9%, respectively. The luminal A subtype was more likely to be diagnosed in older women (P = 0.03) and had a stronger correlation with favorable clinicopathological factors (smaller tumor size, lower histologic grade, and earlier TNM stage) than the triple-negative or HER2 subtypes. Women with triple-negative breast cancer had a higher frequency of family history of breast cancer than women with other subtypes (P = 0.048). The 5-year overall/disease-free survival percentages for the luminal A, luminal B, HER2, and triple-negative subtypes were 92.9%/88.6%, 88.6%/85.1%, 83.2%/79.1%, and 80.7%/76.0%, respectively. A similar pattern was observed in multivariate analyses. Immunotherapy was associated with improved overall and disease-free survival for luminal A breast cancer, but reduced disease-free survival (HR = 2.21, 95% CI, 1.09-4.48) for the HER2 subtype of breast cancer. Conclusions The triple-negative and HER2 subtypes were associated with poorer outcomes compared with the luminal A subtype among these Chinese women. The HER2 subtype was more prevalent in this Chinese population compared with Western populations, suggesting the importance of standardized HER2 detection and anti-HER2 therapy to potentially benefit a high proportion of breast cancer patients in China.Keywords
This publication has 37 references indexed in Scilit:
- Management of breast cancer with targeted agents: importance of heterogenicityNature Reviews Clinical Oncology, 2010
- Soy Food Intake and Breast Cancer SurvivalJama-Journal Of The American Medical Association, 2009
- Molecular Subtypes of Breast Cancer Emerging in Young Women in Taiwan: Evidence for More Than Just Westernization as a Reason for the Disease in AsiaCancer Epidemiology, Biomarkers & Prevention, 2009
- Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast CancerJNCI Journal of the National Cancer Institute, 2009
- Epidemiology of basal-like breast cancerBreast Cancer Research and Treatment, 2007
- Differences in Risk Factors for Breast Cancer Molecular Subtypes in a Population-Based StudyCancer Epidemiology, Biomarkers & Prevention, 2007
- Race, breast cancer subtypes, and survival in the Carolina Breast Cancer StudyJama-Journal Of The American Medical Association, 2006
- Breast cancer classification and prognosis based on gene expression profiles from a population-based studyProceedings of the National Academy of Sciences of the United States of America, 2003
- Repeated observation of breast tumor subtypes in independent gene expression data setsProceedings of the National Academy of Sciences of the United States of America, 2003
- Gene expression profiling predicts clinical outcome of breast cancerNature, 2002